• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Axogen Inc (NQ: AXGN )

    13.27 -2.06 (-13.44%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Axogen Inc

    < Previous 1 2 Next >
    Axogen, Inc Reports Third Quarter 2024 Financial Results and Provides BLA Update
    From Axogen, Inc.
    Via GlobeNewswire
    Axogen, Inc. to report third quarter 2024 financial results and host conference call on November 7, 2024
    From Axogen, Inc.
    Via GlobeNewswire
    Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®
    From Axogen, Inc.
    Via GlobeNewswire
    Axogen Reports Inducement Grant to New Employee Under NASDAQ Listing Rule 5635(C)(4)
    From Axogen, Inc.
    Via GlobeNewswire
    CytoSorbents Appoints Peter J. Mariani Chief Financial Officer
    CytoSorbents CFO Kathleen P. Bloch Retires 
    From CytoSorbents
    Via GlobeNewswire
    Axogen, Inc. Announces New Leadership Appointments
    From Axogen, Inc.
    Via GlobeNewswire
    Axogen, Inc. Reports Second Quarter 2024 Financial Results
    From Axogen, Inc.
    Via GlobeNewswire
    Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
    From Axogen, Inc.
    Via GlobeNewswire
    Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)
    From Axogen, Inc.
    Via GlobeNewswire
    Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™
    From Axogen, Inc.
    Via GlobeNewswire
    Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia
    Showcasing Axogen’s Dedication to Fueling Ohio’s Biotechnology Sector Growth 
    From Axogen, Inc.
    Via GlobeNewswire
    Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®
    From Axogen, Inc.
    Via GlobeNewswire
    Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference
    From Axogen, Inc.
    Via GlobeNewswire
    Axogen, Inc Reports First Quarter 2024 Financial Results
    From Axogen, Inc.
    Via GlobeNewswire
    Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™
    From Axogen, Inc.
    Via GlobeNewswire
    Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
    From Axogen, Inc.
    Via GlobeNewswire
    Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results
    From Axogen, Inc.
    Via GlobeNewswire
    Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024
    From Axogen, Inc.
    Via GlobeNewswire
    Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Axogen, Inc.
    Via GlobeNewswire
    Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap
    From Axogen, Inc.
    Via GlobeNewswire
    Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023
    From Axogen, Inc.
    Via GlobeNewswire
    Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025
    From Axogen, Inc.
    Via GlobeNewswire
    Axogen Announces Promotions on Research and Development Team
    Company Also Announces Departure of Angelo Scopelianos, Ph.D. 
    From Axogen, Inc.
    Via GlobeNewswire
    Axogen, Inc. Appoints Kathy Weiler to its Board of Directors
    Weiler brings 20+ years of strategic and commercial leadership experience to the Axogen, Inc. Board of Directors 
    From Axogen, Inc.
    Via GlobeNewswire
    Axogen Announces Transition of Finance Team Leadership
    Nir Naor Appointed CFO to Replace Peter Mariani as Company Aligns Executive Team with Financial Management Needs for Next Phase of Growth 
    From Axogen, Inc.
    Via GlobeNewswire
    Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Axogen, Inc.
    Via GlobeNewswire
    Axogen, Inc. to Participate at the Piper Sandler 35th Annual Healthcare Conference
    From Axogen, Inc.
    Via GlobeNewswire
    Axogen, Inc. Reports 2023 Third Quarter Financial Results
    From Axogen, Inc.
    Via GlobeNewswire
    Axogen, Inc. to Report Third Quarter 2023 Financial Results and Host Conference Call on November 7, 2023
    From Axogen, Inc.
    Via GlobeNewswire
    Axogen, Inc. Announces Full Launch of Axoguard HA+ Nerve Protector™
    From Axogen, Inc.
    Via GlobeNewswire
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.